Fundraising Fox
Garry A. Neil
InvestorChief Executive Officer, MD at Avalo Therapeutics
Find your path to Garry
Sign up to see every warm intro you have to Garry
- Paths you didn't know you had: your email and LinkedIn already hold routes to Garry. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Garry Neil has served as CEO of Avalo Therapeutics since February 2022, previously acting as its Chief Scientific Officer following the 2020 merger with Aevi Genomic Medicine. He has held senior pharmaceutical roles at Johnson & Johnson, Merck KGaA, and AstraZeneca, and serves on the board of Celldex Therapeutics.
Colleagues at Avalo Therapeutics
Frequently asked questions
- Who is Garry A. Neil?
- Garry Neil has served as CEO of Avalo Therapeutics since February 2022, previously acting as its Chief Scientific Officer following the 2020 merger with Aevi Genomic Medicine. He has held senior pharmaceutical roles at Johnson & Johnson, Merck KGaA, and AstraZeneca, and serves on the board of Celldex Therapeutics.
- Where does Garry A. Neil work?
- Garry A. Neil is Chief Executive Officer, MD at Avalo Therapeutics.
About this profile. Compiled from public sources — Avalo Therapeutics's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights